These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 32810553)

  • 1. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
    Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
    Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
    J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Yumita S; Ogasawara S; Nakagawa M; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kogure T; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Kato J; Kato N
    BMC Gastroenterol; 2023 Mar; 23(1):101. PubMed ID: 37003980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Ohkawa K; Miyazaki M; Mita E; Ito T; Hagiwara H; Yakushijin T; Kodama T; Hikita H; Tatsumi T; Takehara T
    Hepatol Res; 2022 Mar; 52(3):298-307. PubMed ID: 34918428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
    Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
    Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma.
    Choi WM; Kim JY; Choi J; Lee D; Shim JH; Lim YS; Lee HC; Yoo C; Ryu MH; Ryoo BY; Kim KM
    Liver Int; 2021 Sep; 41(9):2189-2199. PubMed ID: 33966338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
    Finn RS; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Gerolami R; Caparello C; Cabrera R; Chang C; Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J
    J Hepatol; 2018 Aug; 69(2):353-358. PubMed ID: 29704513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
    Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
    Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
    Rocha P; Ramal D; Ripoll E; Moliner L; Corbera A; Hardy-Werbin M; Orrillo M; Taus Á; Zuccarino F; Gibert J; Perera-Bel J; Casadevall D; Arriola E
    JTO Clin Res Rep; 2021 Jan; 2(1):100115. PubMed ID: 34589976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.
    Petrioli R; Mazzei MA; Giorgi S; Cesqui E; Gentili F; Francini G; Volterrani L; Francini E
    Anticancer Drugs; 2020 Feb; 31(2):190-195. PubMed ID: 31850916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.